Your browser doesn't support javascript.
loading
Metformin preconditioning protects against myocardial stunning and preserves protein translation in a mouse model of cardiac arrest.
Rutledge, Cody A; Lagranha, Claudia; Chiba, Takuto; Redding, Kevin; Stolz, Donna B; Goetzman, Eric; Sims-Lucas, Sunder; Kaufman, Brett A.
Afiliação
  • Rutledge CA; Division of Cardiology, Vascular Medicine Institute, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Lagranha C; Division of Cardiology, Vascular Medicine Institute, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Chiba T; Rangos Research Center, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA.
  • Redding K; Division of Nephrology, Department of Pediatrics, University of Pittsburgh School, Pittsburgh, PA, USA.
  • Stolz DB; Division of Cardiology, Vascular Medicine Institute, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Goetzman E; Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Sims-Lucas S; Division of Genetic and Genomic Medicine, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA.
  • Kaufman BA; Rangos Research Center, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA.
Article em En | MEDLINE | ID: mdl-37425219
ABSTRACT
Cardiac arrest (CA) causes high mortality due to multi-system organ damage attributable to ischemia-reperfusion injury. Recent work in our group found that among diabetic patients who experienced cardiac arrest, those taking metformin had less evidence of cardiac and renal damage after cardiac arrest when compared to those not taking metformin. Based on these observations, we hypothesized that metformin's protective effects in the heart were mediated by AMPK signaling, and that AMPK signaling could be targeted as a therapeutic strategy following resuscitation from CA. The current study investigates metformin interventions on cardiac and renal outcomes in a non-diabetic CA mouse model. We found that two weeks of metformin pretreatment protects against reduced ejection fraction and reduces kidney ischemia-reperfusion injury at 24 h post-arrest. This cardiac and renal protection depends on AMPK signaling, as demonstrated by outcomes in mice pretreated with the AMPK activator AICAR or metformin plus the AMPK inhibitor compound C. At this 24-h time point, heart gene expression analysis showed that metformin pretreatment caused changes supporting autophagy, antioxidant response, and protein translation. Further investigation found associated improvements in mitochondrial structure and markers of autophagy. Notably, Western analysis indicated that protein synthesis was preserved in arrest hearts of animals pretreated with metformin. The AMPK activation-mediated preservation of protein synthesis was also observed in a hypoxia/reoxygenation cell culture model. Despite the positive impacts of pretreatment in vivo and in vitro, metformin did not preserve ejection fraction when deployed at resuscitation. Taken together, we propose that metformin's in vivo cardiac preservation occurs through AMPK activation, requires adaptation before arrest, and is associated with preserved protein translation.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Mol Cell Cardiol Plus Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Mol Cell Cardiol Plus Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos